02.14.26 -- Pharmaceutical Online Best Of January

This analysis identifies key compliance trends and regional disparities by examining the 2025 U.S. FDA warning letters issued to drug product manufacturers posted between Jan. 1 and Dec. 9, 2025.

With less drugs approved in 2025, it is interesting to see what drugs made it through and if any categories of treatment emerged.

As an icebreaker to start the panel, Teresa Minero from LifeBee asked each presenter to share their top recommendations and major issues to avoid with AI.

Learn about FDA regulation 21 CFR Part 11 and the critical role it plays in ensuring pharmaceutical and medical product manufacturers properly manage and track their data.

We are seeing a rise in the development of “orphan drugs.” Discover challenges and considerations associated with the expedited development and how to successfully work through them.

Stop the cycle of paper-based errors and batch record delays. Find out how a modular, compliance-first manufacturing system accelerates validation, enables real-time traceability, and shortens release cycles.